Voyager

BraunAbility Chrysler ADA Infloor with Simple Stow™: Redefining Accessibility

Retrieved on: 
Tuesday, April 9, 2024
Voyager, Chrysler Voyager, Transport, BraunAbility, Safety

Carmel, IN, April 09, 2024 (GLOBE NEWSWIRE) -- Carmel, IN, 4.9.24 - BraunAbility , the global leader in wheelchair accessibility vehicle solutions, today announced the launch of its latest innovation, the BraunAbility ADA Infloor with Simple Stow™ r amp, the only infloor wheelchair accessible vehicle to meet Buy America requirements.

Key Points: 
  • Carmel, IN, April 09, 2024 (GLOBE NEWSWIRE) -- Carmel, IN, 4.9.24 - BraunAbility , the global leader in wheelchair accessibility vehicle solutions, today announced the launch of its latest innovation, the BraunAbility ADA Infloor with Simple Stow™ r amp, the only infloor wheelchair accessible vehicle to meet Buy America requirements.
  • A user-friendly manual ramp with an extended handle makes ramp deployment and stowing simple, requiring 60% less effort than previous models.
  • Cycle tested and backed by a three-year limited warranty, the BraunAbility Chrysler ADA Infloor with Simple Stow™ ensures reliability and peace of mind for users and operators alike.
  • “The BraunAbility ADA Infloor is just the latest in a long line of best-in-class commercial mobility solutions from BraunAbility,” said Jim Probst, General Manager and Vice President of Commercial Sales at BraunAbility.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 26, 2024
Voyager, Employment, Compensated emancipation, Therapy

The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

Key Points: 
  • The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).
  • The option award became effective on March 25, 2024, and the restricted stock unit award is scheduled to become effective on April 1, 2024.
  • The restricted stock unit award vests annually in equal installments over three years, beginning on the first anniversary of the effective date of grant.
  • Vesting of Dr. Ferguson’s equity awards is subject to Dr. Ferguson’s continued employment with Voyager.

KULR Technology Group Announces a Strategic Contract with Nanoracks for Advanced Space Battery Development

Retrieved on: 
Thursday, March 14, 2024
Growth, Voyager, Partnership, SAN, Research, NASA, CubeSat, Safety, KULR

Based in Webster, Texas, Voyager’s Exploration team is a prominent provider of commercial space services, specializing in satellite deployment, space station research, and the development of space habitats.

Key Points: 
  • Based in Webster, Texas, Voyager’s Exploration team is a prominent provider of commercial space services, specializing in satellite deployment, space station research, and the development of space habitats.
  • The contract underscores KULR's role in spearheading the accelerated development, testing, and early production of a specialized space battery, aimed at enhancing Voyager’s CubeSat applications.
  • For Voyager, it brings KULR's cutting-edge, safe, and innovative battery designs to the forefront of space technology, under an expedited schedule.
  • The KULR ONE Space Platform anticipates significant growth, offering expedited access to wide-ranging, certified battery solutions that are critical to the rapid advancement of space exploration.

Space Executive Clay Mowry Joins Vast as Advisor

Retrieved on: 
Thursday, March 28, 2024
Technology, Aerospace, Manufacturing, Satellite, Astronaut, International Astronautical Federation, CLD, Growth, Blue Origin, Voyager, Blue, IAF, Commercial, NASA, Multimedia

Vast, a pioneer in space habitation technologies, announces the appointment of Clay Mowry as its newest Advisor.

Key Points: 
  • Vast, a pioneer in space habitation technologies, announces the appointment of Clay Mowry as its newest Advisor.
  • In his role as Advisor, Mowry will provide guidance and counsel on the growth of Vast’s commercial space station business.
  • "We are delighted to welcome Clay Mowry to Vast as an Advisor," said Max Haot, CEO of Vast.
  • "I am excited to join Vast as an Advisor and contribute to the company's mission of advancing commercial space stations," said Clay Mowry.

DriveH2 Green Pre-Oscar Gala Raises Bar for Environmental Advocacy

Retrieved on: 
Thursday, March 14, 2024
Automotive, Environmental Health, Automotive Manufacturing, Logistics, Supply Chain Management, Manufacturing, Film & Motion Pictures, Climate Change, Environment, Public Transport, Entertainment, Other Energy, Other Transport, Trucking, Celebrity, Green Technology, Alternative Energy, Energy, Transport, EV, Electric Vehicles, Alternative Vehicles, Fuels, EIN, Climate change, CSI, Shazam, Picard, CSI: Miami, Griselda, EVS, Voyager, Adventure, The Righteous Gemstones, Jury duty, Research, Don Francisco, Policy, The Pussycat Dolls, Kate Linder, Restless, Toyota, Athlete, Quantum, Too Hot, Star Trek, Hall Pass, Secret Service, Roseanne, Petersen Automotive Museum, American Red Cross, Air pollution, Quantum of Solace, Obi-Wan Kenobi, Young, Renewable energy

EIN, through its research, policy advocacy and public outreach, promotes the widespread adoption of diverse zero-emissions solutions.

Key Points: 
  • EIN, through its research, policy advocacy and public outreach, promotes the widespread adoption of diverse zero-emissions solutions.
  • Brian Goldstein, EIN's Executive Director, commented, "The DriveH2 Green Pre-Oscar Gala grows more impactful each year, drawing attention to elegant solutions like hydrogen fuel cells.
  • We're in the early adopter phase of the hydrogen EV movement, facing challenges like infrastructure development and fuel supply head-on.
  • Hosting the event at the Petersen Automotive Museum was particularly fitting, given its commitment to showcasing the evolution of automotive innovation.”

Corporation Joins Starlab Space as Strategic Partner, Equity Owner in Joint Venture

Retrieved on: 
Thursday, April 4, 2024
LEO, Space research, Voyager, Mitsubishi Corporation, Partnership, Airbus Defence and Space, Starlab

HOUSTON, April 4, 2024 /PRNewswire/ -- Starlab Space LLC (Starlab Space), the joint venture between Voyager Space and Airbus, today welcomed Mitsubishi Corporation as a strategic partner and equity owner in Starlab Space.

Key Points: 
  • HOUSTON, April 4, 2024 /PRNewswire/ -- Starlab Space LLC (Starlab Space), the joint venture between Voyager Space and Airbus, today welcomed Mitsubishi Corporation as a strategic partner and equity owner in Starlab Space.
  • This partnership expands Starlab Space's reach beyond a transatlantic partnership and transforms the joint venture into a global organization.
  • "It's an honor to welcome Mitsubishi Corporation as a partner in our joint venture," said Dylan Taylor, Chairman and CEO at Voyager Space.
  • "We are very pleased to welcome Mitsubishi Corporation as a strategic partner in our joint venture with Voyager Space.

Mitsubishi Corporation Joins Starlab Space as Strategic Partner, Equity Owner in Joint Venture

Retrieved on: 
Thursday, April 4, 2024
LEO, Space research, Voyager, Mitsubishi Corporation, Partnership, Airbus Defence and Space, Starlab

HOUSTON, April 4, 2024 /PRNewswire/ -- Starlab Space LLC (Starlab Space), the joint venture between Voyager Space and Airbus, today welcomed Mitsubishi Corporation as a strategic partner and equity owner in Starlab Space.

Key Points: 
  • HOUSTON, April 4, 2024 /PRNewswire/ -- Starlab Space LLC (Starlab Space), the joint venture between Voyager Space and Airbus, today welcomed Mitsubishi Corporation as a strategic partner and equity owner in Starlab Space.
  • This partnership expands Starlab Space's reach beyond a transatlantic partnership and transforms the joint venture into a global organization.
  • "It's an honor to welcome Mitsubishi Corporation as a partner in our joint venture," said Dylan Taylor, Chairman and CEO at Voyager Space.
  • "We are very pleased to welcome Mitsubishi Corporation as a strategic partner in our joint venture with Voyager Space.

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024
Rare disease, Therapy, Regenerative Medicine Advanced Therapy, FAP, Concha bullosa, Sulindac, Chemistry, Fast track (FDA), Muscular dystrophy, FDA, Sensation, News, Eflornithine, DMD, Prader–Willi syndrome, BLA, Chromosome, RDEB, PDUFA, Skin, Voyager, PRISM, Duchenne muscular dystrophy, Safety, Neurocrine Biosciences, Rare Disease Day, Genetics, Fatigue, Walking, PWS, Patient, DSM-IV codes, Medicine, Disease, Exosome, FA, CMC, Priority review, Pharmaceutical industry

All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders.

Key Points: 
  • All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders.
  • Today on Rare Disease Day, PRISM MarketView highlights emerging companies working to deliver life changing treatments for those living with rare diseases.
  • RDEB is a severe rare disease characterized by extremely fragile, and extensive blistering and wounds.
  • Capricor is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

Retrieved on: 
Wednesday, February 21, 2024
Therapy, Webcast, Voyager, Telephone

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024.

Key Points: 
  • LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024.
  • Subsequently, the Company will host a conference call and webcast at 4:30 p.m.
  • Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.
  • The replay will be available for at least 30 days following the conclusion of the call.

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

Retrieved on: 
Tuesday, February 20, 2024
BBB, Traffic barrier, Messenger, Voyager, Conference, MicroRNA, RNA, Therapy, Pharmacokinetics, Patient, Cognition, VY, IND, AAV, DSM-IV codes, PET, Mouse, Brain, Vaccine

LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy program will be presented at the upcoming 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024), taking place March 5-9, 2024, in Lisbon, Portugal.

Key Points: 
  • Tau Silencing Gene Therapy Program:
    Intravenous administration of BBB-penetrant AAV containing primary artificial microRNA targeting tau reduces tau broadly and robustly in hTau mouse brain.
  • Voyager’s tau silencing gene therapy program combines vectorized tau-targeted siRNA with a proprietary, blood-brain barrier (BBB)-penetrant capsid derived from the Company’s TRACER™ discovery platform.
  • Based on these data, Voyager has advanced this program into late research and expects to file an investigational new drug (IND) application in 2026.
  • Pharmacokinetics and tolerability of VY-TAU01, an anti-tau antibody for the treatment of Alzheimer’s disease, in P301S mouse and nonhuman primate.